Scott Braunstein was appointed Chief Executive Officer of Marinus in August 2019, executive chairman in February 2019 and has served on our Board since September 2018.
Scott Braunstein, M.D., Chief Executive Officer & Director
Scott Braunstein was appointed Chief Executive Officer of Marinus in August 2019, executive chairman in February 2019 and has served on our Board since September 2018. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief strategy officer and chief operating officer at Pacira Pharmaceuticals, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as portfolio manager of the JP Morgan Global Healthcare Fund responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. Dr. Braunstein is currently on the board at Trevena Inc., Ziopharm Oncology Inc. and Constellation Pharmaceuticals. He previously served as board member of Esperion Pharmaceuticals and Protara Theraputics Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine.
Ed has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage.
Edward F. Smith, Vice President, Chief Financial Officer, Secretary and Treasurer
Ed has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage. As CFO of Marinus, Ed oversees finance, accounting, information technology, and program management. Throughout his career, he has raised hundreds of millions of dollars from IPOs, follow-on equity raises, private placements, convertible securities, and debt issuances. Prior to Marinus, Ed served as CFO of PolyMedix, Inc., and executive director of finance at InKine Pharmaceutical Company, Inc., where he assisted with the acquisition of the company by Salix Pharmaceuticals, Inc. Earlier in his career, Ed held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte & Touche, LLP. Ed is currently a member of the board of directors at Benitec Biopharma, Inc., a development-stage biotechnology company focused on the advancement of novel genetic medicines.
Ed holds a B.S. in business administration from the University of Hartford and was licensed as a Certified Public Accountant in Pennsylvania.
Dr. Hulihan brings close to 30 years of experience in clinical drug development, medical affairs and research in numerous conditions in neurology and psychiatry including epilepsy, ADHD, schizophrenia and mood disorders.
Joe Hulihan, M.D., Chief Medical Officer
Dr. Hulihan brings close to 30 years of experience in clinical drug development, medical affairs and research in numerous conditions in neurology and psychiatry including epilepsy, ADHD, schizophrenia and mood disorders. He is a board-certified neurologist and clinical neurophysiologist. Most recently, he was principal at Paradigm Neuroscience, where he provided consulting services including clinical and strategic support for neurotherapeutics in all phases of development. Prior to that, Dr. Hulihan spent 15 years at Johnson & Johnson in roles of increasing responsibility with a primary focus on neurology and psychiatry. Most recently he served as Global Medical Affairs Leader, Neuroscience (mood disorders) at Janssen Global Services, LLC. Other roles included Vice President, CNS Medical Affairs at Janssen and Director, CNS Research, Clinical Affairs at Ortho-McNeil Pharmaceutical. Dr. Hulihan has served as a principal investigator, member of the clinical development team, group supervisor, and study physician on more than 25 late-stage CNS focused clinical trials and authored more than 70 published papers. He received his medical degree from Drexel University School of Medicine, with Honors in Neurology.
T.J. has over 25 years of transactional and commercial experience in the life sciences and health care industries.
Thomas J. Lyons, Vice President, Corporate & Business Development and Commercial Planning
T.J. has over 25 years of transactional and commercial experience in the life sciences and health care industries. Prior to joining Marinus, T.J. was a managing partner at Fidem Capital, a boutique, transactional advisory firm focused on mergers & acquisitions, equity financings, and corporate development for health care and technology companies in the lower middle market. T.J. has held corporate & business development positions at Oscient Pharmaceuticals and Cempra Pharmaceuticals as well as a variety of commercial positions of increasing responsibility at Abbott Laboratories and Cephalon, Inc. He has also been a managing partner of Vector Advisory, a consultancy concentrating on corporate development and strategic advisory to life sciences companies. Throughout his various roles, T.J. has completed a wide array of transactions including product in-/out-licensing, M&A, asset acquisitions/divestitures/spin-outs, financings, co-promotions, joint ventures, and strategic alliances for private and public entities ranging from start-ups to Fortune 50 international corporations.
T.J. holds a B.S. in business administration & marketing from Boston College and an M.B.A in finance & entrepreneurship from Babson College. He maintains FINRA Series 7, 63 & 79 licenses for securities transactions and investment banking.
Dave is a global pharmaceutical development and operations executive with more than 30 years experience in advancing complex, technology-based products from proof of concept through commercialization.
David A. Czekai, Vice President Manufacturing
Dave is a global pharmaceutical development and operations executive with more than 30 years experience in advancing complex, technology-based products from proof of concept through commercialization. He is a pioneer in the areas of developing and advancing nanotechnology to commercial success for multiple FDA-approved drug products. At Marinus, Dave leads drug product development and manufacturing initiatives for all clinical programs. Dave started his career at Eastman Kodak where he was co-inventor of Kodak’s NanoCrystal® technology platform, and co-founder of Kodak’s pharmaceutical subsidiary NanoSystems LLC (later acquired by Elan Corporation). While at Elan (later acquired by Alkermes), Dave led the NanoCrystal® business, including responsibility for drug delivery product development and commercialization within the global pharmaceutical industry. After his tenure at Alkermes, Dave founded and served as president of NanoCentrix LLC, a technology start-up engaged in development and commercialization of the next generation of nanotechnology materials and manufacturing processes.
Dave holds B.S. and M.S. degrees in chemical engineering from Clarkson University and has been inducted to Omega Chi Epsilon and Tau Beta PI National Engineering Honor Societies.
Kim has 20 years of experience in regulatory affairs at specialty pharmaceutical companies.
Kimberly McCormick, PharmD, Vice President Regulatory Affairs
Kim has 20 years of experience in regulatory affairs at specialty pharmaceutical companies. As Vice President of Regulatory Affairs at Marinus, Kim leads the regulatory strategy and interactions with health authorities. Under her leadership, the regulatory team fosters innovation and efficiency in developing new treatments for CNS disorders, while ensuring compliance with laws and regulations via transparent and data-driven decision-making. Before joining Marinus, Kim was Senior Director, Global Regulatory Lead at Shire Pharmaceuticals, where she was part of the team responsible for all aspects of regulatory affairs for a broad range of programs in multiple therapeutic areas and pharmaceutical technologies. Prior to Shire, she held roles of increasing responsibility at Wyeth Pharmaceuticals and Pfizer. Kim holds a Doctor of Pharmacy degree from the University of the Sciences of Philadelphia